Development of a 3D multi-modal perfusion-thermal electrode system

总结/摘要： 标题：3D多模式灌注-热电极系统的开发 影像引导介入技术的进步极大地改善了 患者的恶性肿瘤。在不同的介入肿瘤学技术中，热消融，如 如射频消融（RFA）和微波消融（MWA），已成为 治疗不可切除的原发性和转移性恶性肿瘤。然而，肿瘤复发后- 由于不完全消融，经常发生中等（3- 5cm）至大（5-7 cm）损伤的热消融 肿瘤边缘。迄今为止，还没有一种理想的有效的图像引导介入方法 中型至大型实体器官恶性肿瘤的管理。 这个项目是专门设计来克服关键的临床问题-持久性或 通过开发一种新的三种治疗方法， 三维（3D）多模式灌注-热电极系统。为此，我们提出了两个 具体目标：（1）目的一：设计并研制新型三维多模态灌注-热电极 专门为使用RFA诱导的肿瘤周围射频热疗（RFH）而构建的系统， 增强肿瘤边缘的直接化学治疗破坏;和（2）目的II：验证 通过优化技术方案，新的多模式电极系统的技术可行性 通过在原位肝肿瘤活体动物模型中进行一系列临床前研究。作为第一步， 新技术的发展，我们将主要集中在肝肿瘤的治疗，通过使用第一- 线化疗。如果成功，我们将把它在治疗恶性肿瘤方面的应用扩展到其他领域。 更先进的治疗方法，如基因治疗和免疫治疗。 该项目的成功将彻底改变目前的热消融技术， 在根除中大型恶性病变方面取得了重大进展，不仅在肝脏， 在其他实体器官中也是如此。这反过来将大大提高患者的生存率和生活质量 患有中到大型恶性肿瘤

Summary/Abstract: Title: Development of a 3D multi-modal perfusion-thermal electrode system Advances in image-guided interventional technologies have greatly improved the management of malignancies in patients. Among different interventional oncologic techniques, thermal ablations, such as radiofrequency ablation (RFA) and microwave ablation (MWA), have become the principal tools for treatment of unresectable primary and metastatic malignancies. However, tumor recurrence post- thermal ablation of medium (3-5 cm) to large (5-7 cm) lesions often occurs due to incomplete ablation of tumor margins. To date, there is no an ideal image-guided interventional method for effective management of medium-to-large solid organ malignancies. This project is specifically designed to conquer the critical clinical problem ─ persistence or recurrence of medium-to-large malignancies post-thermal ablation, by development of a novel three- dimensional (3D) multi-modal perfusion-thermal electrode system. To this end, we have proposed two specific goals: (1) Aim I: to design and develop the novel 3D multi-modal perfusion-thermal electrode system that is specifically built for using RFA-induced peri-tumoral RF hyperthermia (RFH) to enhance direct chemotherapeutic destruction of tumor margins; and (2) Aim II: to validate the technical feasibility of the new multi-modal electrode system with optimizing the technical protocols via serial preclinical studies in living animal models with orthotopic liver tumors. As the first step of the new technique development, we will primarily focus on the treatment of hepatic tumors by using first- line chemotherapeutics. If successful, we will extend its application in treating malignancies to other organs with more advanced therapies, such as gene therapy and immunotherapy. The success of this project will revolutionize current thermal ablation technology, leading to significant advancement in eradicating medium-to-large malignant lesions, not only in the liver but also in other solid organs. This will, in turn, greatly improve survival and quality of life of patients suffering from medium-to-large malignancies.